Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Viking Therapeutics (VKTX) Amortization - Intangibles (2016 - 2018)

Historic Amortization - Intangibles for Viking Therapeutics (VKTX) over the last 5 years, with Q2 2018 value amounting to $146000.0.

  • Viking Therapeutics' Amortization - Intangibles fell 5667.66% to $146000.0 in Q2 2018 from the same period last year, while for Mar 2019 it was $146000.0, marking a year-over-year decrease of 8684.68%. This contributed to the annual value of $404000.0 for FY2018, which is 6851.13% down from last year.
  • Latest data reveals that Viking Therapeutics reported Amortization - Intangibles of $146000.0 as of Q2 2018, which was down 5667.66% from $258000.0 recorded in Q1 2018.
  • Viking Therapeutics' 5-year Amortization - Intangibles high stood at $524977.0 for Q2 2016, and its period low was $6379.0 during Q1 2014.
  • Over the past 5 years, Viking Therapeutics' median Amortization - Intangibles value was $257000.0 (recorded in 2017), while the average stood at $273697.2.
  • Per our database at Business Quant, Viking Therapeutics' Amortization - Intangibles soared by 259564.2% in 2015 and then plummeted by 5667.66% in 2018.
  • Viking Therapeutics' Amortization - Intangibles (Quarter) stood at $294310.0 in 2014, then decreased by 18.28% to $240516.0 in 2015, then surged by 79.29% to $431227.0 in 2016, then plummeted by 39.94% to $259000.0 in 2017, then tumbled by 43.63% to $146000.0 in 2018.
  • Its Amortization - Intangibles was $146000.0 in Q2 2018, compared to $258000.0 in Q1 2018 and $259000.0 in Q4 2017.